Scientific jobs

As a scientific officer at EMA, you will typically be responsible for activities related to human or veterinary medicines in areas such as procedure and scientific management, scientific committee support, pharmacovigilance, and inspections and quality.

You will have obtained a degree in a science field and have proven work experience in the field of medicines regulation from the pharmaceutical industry, a national competent authority or academia. You will have knowledge and understanding of scientific aspects of medicines development, clinical trials methodology, signal detection and pharmacoepidemiology. You will be a curious, solution-driven team player who can communicate verbally and in writing with various audiences.

Search results for "". Page 1 of 2, Results 1 to 25 of 30
Title Deadline for application Type of position
Trainee (Evidence based medicines for immune and inflammatory diseases and regulatory pathways) 20 May 2024 23:59 CET Trainee
Trainee (Data analysis to improve Marketing Authorisation Application Validation process & guidance) 20 May 2024 23:59 CET Trainee
Trainee (Strengthening Knowledge management of the EMA's scientific committees) 20 May 2024 23:59 CET Trainee
Trainee (Healthcare professionals' involvement in referral procedures) 20 May 2024 23:59 CET Trainee
Trainee (Preparing for new pharma legislation: fostering framework for repurposed drugs) 20 May 2024 23:59 CET Trainee
Trainee (Develop EMA's translational use of PBPK models from dossier to labelling) 20 May 2024 23:59 CET Trainee
Trainee (Inspection Office: Compliance related data collection and analysis) 20 May 2024 23:59 CET Trainee
Trainee (Medicines for children - status of authorisation of medicines for children in the EU) 20 May 2024 23:59 CET Trainee
Trainee (Inspection Office: Knowledge management and process improvement) 20 May 2024 23:59 CET Trainee
Trainee (Implementation of WOM Quality Domain - set-up of ESECs on Biologicals and Chemicals) 20 May 2024 23:59 CET Trainee
Trainee (haemato-oncology - Advanced therapies and haematological diseases office) 20 May 2024 23:59 CET Trainee
Trainee (Replacement of Medicinal Product Dictionary (Art.57) & related international activities) 20 May 2024 23:59 CET Trainee
Trainee (Stakeholder listening on health threats and Patient Experience Data (PED) ) 20 May 2024 23:59 CET Trainee
Trainee (Knowledge management for clinical trials) 20 May 2024 23:59 CET Trainee
Trainee (medicine development activities by the academic sector) 20 May 2024 23:59 CET Trainee
Trainee (change management activities for ESMP)
Trainee (change management activities for ESMP) 20 May 2024 23:59 CET Trainee
20 May 2024 23:59 CET Trainee
Trainee (Small and Medium sized Enterprises Office) 20 May 2024 23:59 CET Trainee
Trainee (Evidence based medicines for rare (non oncology) diseases and regulatory pathways) 20 May 2024 23:59 CET Trainee
Trainee (New Pharmaceutical Legislation (Chapter X) ) 20 May 2024 23:59 CET Trainee
Trainee (not-for-profit developer organisations)
Trainee (not-for-profit developer organisations) 20 May 2024 23:59 CET Trainee
20 May 2024 23:59 CET Trainee
Trainee (Innovation and Development Accelerator)
Trainee (Innovation and Development Accelerator) 20 May 2024 23:59 CET Trainee
20 May 2024 23:59 CET Trainee
Trainee (Innovative veterinary medicinal products) 20 May 2024 23:59 CET Trainee
Trainee (Veterinary Pharmacovigilance)
Trainee (Veterinary Pharmacovigilance) 20 May 2024 23:59 CET Trainee
20 May 2024 23:59 CET Trainee
Trainee (Change management linked to the use of RWE in medicine regulation) 20 May 2024 23:59 CET Trainee
Trainee (Analysing clinical trials data: From application to results) 20 May 2024 23:59 CET Trainee

What is it like to work in the Human Medicines Division?

Regulatory Science to 2025 - Shaping the future

 

As science and technology advance and bring potential new treatments and diagnostic tools, regulatory science must advance in tandem so that these can be correctly, rigorously and efficiently assessed. Examples of the transformational research that is having a significant impact on the regulatory science agenda include cell-based therapies, genomics-based diagnostics, drug-device combinations, novel clinical trial design, predictive toxicology, real-world evidence, and ‘big data’ and artificial intelligence.